AFT Pharmaceuticals Limited (AFT.NZ)
NZD 2.64
(1.54%)
NZD 2.64
(1.54%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 195.41 Million NZD | 25.41% |
| 2023 | 155.82 Million NZD | 20.01% |
| 2022 | 129.83 Million NZD | 15.04% |
| 2021 | 112.86 Million NZD | 7.24% |
| 2020 | 105.24 Million NZD | 24.0% |
| 2019 | 84.87 Million NZD | 6.25% |
| 2018 | 79.88 Million NZD | 15.69% |
| 2017 | 69.04 Million NZD | 19.73% |
| 2016 | 57.67 Million NZD | 2.54% |
| 2015 | 56.24 Million NZD | 14.92% |
| 2014 | 48.93 Million NZD | 21.25% |
| 2013 | 40.36 Million NZD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 41.8 Million NZD | -54.0% |
| 2024 Q2 | 83.61 Million NZD | 100.0% |
| 2024 Q4 | 55.89 Million NZD | 0.0% |
| 2024 Q3 | 55.89 Million NZD | -33.15% |
| 2024 FY | 195.41 Million NZD | 25.41% |
| 2023 Q3 | 45.44 Million NZD | -30.88% |
| 2023 Q2 | 65.75 Million NZD | 100.0% |
| 2023 FY | 155.82 Million NZD | 20.01% |
| 2023 Q4 | 90.89 Million NZD | 100.0% |
| 2023 Q1 | 32.87 Million NZD | -56.05% |
| 2022 Q1 | 27.75 Million NZD | -56.82% |
| 2022 FY | 129.83 Million NZD | 15.04% |
| 2022 Q4 | 74.8 Million NZD | 100.0% |
| 2022 Q3 | 37.4 Million NZD | -32.63% |
| 2022 Q2 | 55.51 Million NZD | 100.0% |
| 2021 Q2 | 48.82 Million NZD | 100.0% |
| 2021 Q3 | 32.14 Million NZD | -34.16% |
| 2021 Q4 | 64.28 Million NZD | 100.0% |
| 2021 FY | 112.86 Million NZD | 7.24% |
| 2021 Q1 | 24.41 Million NZD | -58.38% |
| 2020 Q1 | 23.47 Million NZD | 0.56% |
| 2020 Q2 | 46.94 Million NZD | 100.0% |
| 2020 Q4 | 58.65 Million NZD | 100.0% |
| 2020 Q3 | 29.32 Million NZD | -37.53% |
| 2020 FY | 105.24 Million NZD | 24.0% |
| 2019 Q1 | 19.22 Million NZD | -13.84% |
| 2019 FY | 84.87 Million NZD | 6.25% |
| 2019 Q4 | 23.34 Million NZD | 0.0% |
| 2019 Q3 | 23.34 Million NZD | 21.45% |
| 2019 Q2 | 19.22 Million NZD | 0.0% |
| 2018 FY | 79.88 Million NZD | 15.69% |
| 2018 Q2 | 18.28 Million NZD | 0.0% |
| 2018 Q3 | 22.3 Million NZD | 22.03% |
| 2018 Q4 | 22.3 Million NZD | 0.0% |
| 2018 Q1 | 18.28 Million NZD | -7.25% |
| 2017 Q1 | 14.89 Million NZD | -76.73% |
| 2017 Q3 | 19.7 Million NZD | 32.33% |
| 2017 FY | 69.04 Million NZD | 19.73% |
| 2017 Q4 | 19.7 Million NZD | 0.0% |
| 2017 Q2 | 14.89 Million NZD | 0.0% |
| 2016 Q2 | 14.77 Million NZD | 0.0% |
| 2016 FY | 57.67 Million NZD | 2.54% |
| 2016 Q4 | 64.01 Million NZD | 271.41% |
| 2016 Q3 | 17.23 Million NZD | 16.68% |
| 2016 Q1 | 14.77 Million NZD | -7.93% |
| 2015 Q4 | 16.04 Million NZD | 0.0% |
| 2015 Q2 | 12.07 Million NZD | 0.0% |
| 2015 FY | 56.24 Million NZD | 14.92% |
| 2015 Q3 | 16.04 Million NZD | 32.85% |
| 2015 Q1 | 12.07 Million NZD | 0.0% |
| 2014 FY | 48.93 Million NZD | 21.25% |
| 2013 FY | 40.36 Million NZD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Greenfern Industries Limited | 377.57 Thousand NZD | -51654.769% |
| Rua Bioscience Limited | 85.83 Thousand NZD | -227553.576% |